The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C

Mosaburo Kainuma, Jun Hayashi, Shinya Sakai, Kazuaki Imai, Naoki Mantani, Kazufumi Kohta, Tadamichi Mitsuma, Yutaka Shimada, Seizaburo Kashiwagi, Katsutoshi Terasawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The purpose of this study was to determine if the adverse effects of interferon (IFN) in hepatitis C patients could be reduced by treatment with Japanese Oriental (Kampo) medicine. Twelve patients with chronic hepatitis C were treated with a combination of IFN-β and either Mao-to or Dai-seiryu-to (groups A and B), and 16 patients were treated with IFN-β alone (group C). Mao-to was administered to eight patients and Dai-seiryu-to was administered to four in groups A and B, respectively. Adverse effects were evaluated by clinical and laboratory examinations. The severity of symptoms was daily self-classified into four categories (1: none, 2: very slight, 3: moderate, and 4: serious), using a questionnaire consisting of 29 items. Scores of symptom such as discomfort and fever in group A, and discomfort, general malaise, paresthesia and arthralgia in group B were significantly lower than those in group C (p < 0.05). In all patients, HCV-RNA was negative at the end of the treatment, and serum alanine aminotransferase (ALT) levels had normalized transiently in all group A and B patients with genotype 1 b by 2 weeks after cessation of IFN treatment. This study indicates that Kampo medicines are useful for reducing the adverse effects accompanying IFN treatment in patients with chronic hepatitis C without reducing the antiviral effects.

Original languageEnglish
Pages (from-to)355-367
Number of pages13
JournalAmerican Journal of Chinese Medicine
Volume30
Issue number2-3
DOIs
Publication statusPublished - Dec 1 2002

Fingerprint

Kampo Medicine
Herbal Medicine
Chronic Hepatitis C
Interferons
East Asian Traditional Medicine
Withholding Treatment
Paresthesia
Arthralgia
Hepatitis C
Alanine Transaminase
Antiviral Agents
Fever
Therapeutics
Genotype
RNA

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Cite this

The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C. / Kainuma, Mosaburo; Hayashi, Jun; Sakai, Shinya; Imai, Kazuaki; Mantani, Naoki; Kohta, Kazufumi; Mitsuma, Tadamichi; Shimada, Yutaka; Kashiwagi, Seizaburo; Terasawa, Katsutoshi.

In: American Journal of Chinese Medicine, Vol. 30, No. 2-3, 01.12.2002, p. 355-367.

Research output: Contribution to journalArticle

Kainuma, M, Hayashi, J, Sakai, S, Imai, K, Mantani, N, Kohta, K, Mitsuma, T, Shimada, Y, Kashiwagi, S & Terasawa, K 2002, 'The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C', American Journal of Chinese Medicine, vol. 30, no. 2-3, pp. 355-367. https://doi.org/10.1142/S0192415X02000284
Kainuma, Mosaburo ; Hayashi, Jun ; Sakai, Shinya ; Imai, Kazuaki ; Mantani, Naoki ; Kohta, Kazufumi ; Mitsuma, Tadamichi ; Shimada, Yutaka ; Kashiwagi, Seizaburo ; Terasawa, Katsutoshi. / The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C. In: American Journal of Chinese Medicine. 2002 ; Vol. 30, No. 2-3. pp. 355-367.
@article{2a0c25be4bde4cfcb727ded4d0493a11,
title = "The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C",
abstract = "The purpose of this study was to determine if the adverse effects of interferon (IFN) in hepatitis C patients could be reduced by treatment with Japanese Oriental (Kampo) medicine. Twelve patients with chronic hepatitis C were treated with a combination of IFN-β and either Mao-to or Dai-seiryu-to (groups A and B), and 16 patients were treated with IFN-β alone (group C). Mao-to was administered to eight patients and Dai-seiryu-to was administered to four in groups A and B, respectively. Adverse effects were evaluated by clinical and laboratory examinations. The severity of symptoms was daily self-classified into four categories (1: none, 2: very slight, 3: moderate, and 4: serious), using a questionnaire consisting of 29 items. Scores of symptom such as discomfort and fever in group A, and discomfort, general malaise, paresthesia and arthralgia in group B were significantly lower than those in group C (p < 0.05). In all patients, HCV-RNA was negative at the end of the treatment, and serum alanine aminotransferase (ALT) levels had normalized transiently in all group A and B patients with genotype 1 b by 2 weeks after cessation of IFN treatment. This study indicates that Kampo medicines are useful for reducing the adverse effects accompanying IFN treatment in patients with chronic hepatitis C without reducing the antiviral effects.",
author = "Mosaburo Kainuma and Jun Hayashi and Shinya Sakai and Kazuaki Imai and Naoki Mantani and Kazufumi Kohta and Tadamichi Mitsuma and Yutaka Shimada and Seizaburo Kashiwagi and Katsutoshi Terasawa",
year = "2002",
month = "12",
day = "1",
doi = "10.1142/S0192415X02000284",
language = "English",
volume = "30",
pages = "355--367",
journal = "American Journal of Chinese Medicine",
issn = "0192-415X",
publisher = "World Scientific Publishing Co. Pte Ltd",
number = "2-3",

}

TY - JOUR

T1 - The efficacy of herbal medicine (Kampo) in reducing the adverse effects of IFN-β in chronic hepatitis C

AU - Kainuma, Mosaburo

AU - Hayashi, Jun

AU - Sakai, Shinya

AU - Imai, Kazuaki

AU - Mantani, Naoki

AU - Kohta, Kazufumi

AU - Mitsuma, Tadamichi

AU - Shimada, Yutaka

AU - Kashiwagi, Seizaburo

AU - Terasawa, Katsutoshi

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The purpose of this study was to determine if the adverse effects of interferon (IFN) in hepatitis C patients could be reduced by treatment with Japanese Oriental (Kampo) medicine. Twelve patients with chronic hepatitis C were treated with a combination of IFN-β and either Mao-to or Dai-seiryu-to (groups A and B), and 16 patients were treated with IFN-β alone (group C). Mao-to was administered to eight patients and Dai-seiryu-to was administered to four in groups A and B, respectively. Adverse effects were evaluated by clinical and laboratory examinations. The severity of symptoms was daily self-classified into four categories (1: none, 2: very slight, 3: moderate, and 4: serious), using a questionnaire consisting of 29 items. Scores of symptom such as discomfort and fever in group A, and discomfort, general malaise, paresthesia and arthralgia in group B were significantly lower than those in group C (p < 0.05). In all patients, HCV-RNA was negative at the end of the treatment, and serum alanine aminotransferase (ALT) levels had normalized transiently in all group A and B patients with genotype 1 b by 2 weeks after cessation of IFN treatment. This study indicates that Kampo medicines are useful for reducing the adverse effects accompanying IFN treatment in patients with chronic hepatitis C without reducing the antiviral effects.

AB - The purpose of this study was to determine if the adverse effects of interferon (IFN) in hepatitis C patients could be reduced by treatment with Japanese Oriental (Kampo) medicine. Twelve patients with chronic hepatitis C were treated with a combination of IFN-β and either Mao-to or Dai-seiryu-to (groups A and B), and 16 patients were treated with IFN-β alone (group C). Mao-to was administered to eight patients and Dai-seiryu-to was administered to four in groups A and B, respectively. Adverse effects were evaluated by clinical and laboratory examinations. The severity of symptoms was daily self-classified into four categories (1: none, 2: very slight, 3: moderate, and 4: serious), using a questionnaire consisting of 29 items. Scores of symptom such as discomfort and fever in group A, and discomfort, general malaise, paresthesia and arthralgia in group B were significantly lower than those in group C (p < 0.05). In all patients, HCV-RNA was negative at the end of the treatment, and serum alanine aminotransferase (ALT) levels had normalized transiently in all group A and B patients with genotype 1 b by 2 weeks after cessation of IFN treatment. This study indicates that Kampo medicines are useful for reducing the adverse effects accompanying IFN treatment in patients with chronic hepatitis C without reducing the antiviral effects.

UR - http://www.scopus.com/inward/record.url?scp=1042309282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042309282&partnerID=8YFLogxK

U2 - 10.1142/S0192415X02000284

DO - 10.1142/S0192415X02000284

M3 - Article

C2 - 12230024

AN - SCOPUS:1042309282

VL - 30

SP - 355

EP - 367

JO - American Journal of Chinese Medicine

JF - American Journal of Chinese Medicine

SN - 0192-415X

IS - 2-3

ER -